Tilray
pharmaceutical and cannabis company
TLRY Nasdaq
ISIN US88688T1007 SEC CIK 1731348 LEI 549300Y4V60733TO1478
Follow Tilray
Weekly email: filings, results
Revenue, last quarter
$257.1M
+22.7% vs same quarter last year
Net income
−$43.1M
−13297.8% vs same quarter last year
EPS, diluted
−$0.32
Operating cash flow
−$16.5M
−1133.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $915.5M | −$121.4M |
| FY25 | $821.3M | −$2.2B |
| FY24 | $788.9M | −$245M |
| FY23 | $627.1M | −$1.5B |
| FY22 | $628.4M | −$476.8M |
| FY20 | $405.3M | −$102.5M |
| FY18 | $20.5M | −$7.8M |
| FY17 | $12.6M | −$7.9M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY26 | 28.4% | −6.9% | −13.3% |
| FY25 | 29.3% | −277.9% | −266.3% |
| FY24 | 28.3% | −22.1% | −31.1% |
| FY23 | 23.4% | −218.4% | −231.6% |
| FY22 | 18.6% | −97.1% | −75.9% |
| FY20 | 23.7% | −25.7% | −25.3% |
| FY18 | 55.4% | −36.5% | −38% |
| FY17 | 21.1% | −55.7% | −62.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | - |
| FY25 | −$127.5M |
| FY24 | −$60.2M |
| FY23 | −$12.9M |
| FY22 | −$211.3M |
| FY20 | −$174.4M |
| FY18 | −$16.9M |
| FY17 | −$3.8M |
- Tilray
- Healthcare median
Show the numbers
| Year | Tilray | Healthcare median |
|---|---|---|
| FY26 | −13.3% | −11.1% |
| FY25 | −266.3% | −30.6% |
| FY24 | −31.1% | −47% |
| FY23 | −231.6% | −58% |
| FY22 | −75.9% | −80.4% |
| FY20 | −25.3% | −62.2% |
| FY18 | −38% | −49.6% |
| FY17 | −62.3% | −45.9% |